You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Regeneron
since
auto-detected in 14 stories
22 days ago
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest moves premarket: Regeneron, Dominion Energy, Macy's & more ⊕
These are the stocks posting the largest moves premarket.
Regeneron drops after skin cancer treatment misses late-stage trial goal ⊖
The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS).
46 days ago
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss ⊕
Regeneron will make its newly approved gene therapy available for free in the U.S. The company hasn't yet decided how much it will charge in other countries.
47 days ago
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free ⊕
Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.
6 months ago
Stocks making the biggest moves midday: Nvidia, Walmart, Strategy, Regeneron & more ○
These are the stocks posting the largest moves in midday trading.
10 months ago
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days ○
found
Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo Nordisk.
12 months ago
23andMe to delist from Nasdaq, deregister with SEC ○
Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million.
23andMe sold out of bankruptcy to Regeneron ○
Drugmaker’s takeover could raise privacy concerns among genetics start-up’s 15mn users
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million ○
Regeneron is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction.